Literature DB >> 3513734

The Boston Center for Liver Transplantation (BCLT). Initial experience of a new surgical consortium.

R L Jenkins.   

Abstract

Improved survival following liver transplantation has led to a rapid increase in the number of centers providing this expensive and demanding therapy. In January 1984, four Boston hospitals launched a cooperative program known as the Boston Center for Liver Transplantation (BCLT). From January 1984 through July 1985, 47 liver transplantations were performed in 41 patients ranging in age from 8 months to 60 years. Donor organs were retrieved from 22 states within a 2,500-mile radius. Thirty-five of the 47 procedures were performed by teams consisting of surgeons from at least two BCLT member hospitals. Twelve-month actuarial survival was 54.1% without significant institutional variability. The BCLT has developed into a unique transplant consortium capable of sharing manpower, equipment, and organs without sacrificing quality of care of disrupting preexisting medical services.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3513734     DOI: 10.1001/archsurg.1986.01400040060009

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

1.  Experience with transplantation in the treatment of liver cancer.

Authors:  R L Jenkins; C W Pinson; M D Stone
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Survival from hepatic transplantation. Relationship of protein synthesis to histological abnormalities in patient selection and postoperative management.

Authors:  R L Jenkins; G H Clowes; S Bosari; R H Pearl; U Khettry; C Trey
Journal:  Ann Surg       Date:  1986-10       Impact factor: 12.969

3.  Size reduction of the donor liver is a safe way to alleviate the shortage of size-matched organs in pediatric liver transplantation.

Authors:  J B Otte; J de Ville de Goyet; E Sokal; D Alberti; D Moulin; B de Hemptinne; F Veyckemans; L van Obbergh; M Carlier; P Clapuyt
Journal:  Ann Surg       Date:  1990-02       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.